Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $8.81 Average Target Price from Analysts

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have been assigned a consensus recommendation of “Hold” from the nineteen research firms that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, fifteen have given a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $8.81.

SAGE has been the subject of several recent research reports. Piper Sandler cut their price target on Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, January 2nd. Wedbush reaffirmed a “neutral” rating and issued a $6.00 target price on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Stifel Nicolaus lowered their price target on shares of Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating on the stock in a research report on Monday, December 16th. Canaccord Genuity Group cut their price objective on shares of Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating for the company in a research report on Wednesday, February 12th. Finally, Scotiabank decreased their target price on shares of Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating on the stock in a report on Wednesday, February 12th.

Sage Therapeutics Stock Down 1.1 %

Sage Therapeutics stock opened at $7.86 on Friday. The company has a fifty day simple moving average of $7.51 and a 200-day simple moving average of $6.73. The firm has a market capitalization of $483.24 million, a price-to-earnings ratio of -1.19 and a beta of 0.82. Sage Therapeutics has a 52-week low of $4.62 and a 52-week high of $17.79.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. On average, research analysts anticipate that Sage Therapeutics will post -3.52 EPS for the current fiscal year.

Institutional Investors Weigh In On Sage Therapeutics

Several institutional investors have recently modified their holdings of the company. Picton Mahoney Asset Management increased its holdings in Sage Therapeutics by 126.0% in the fourth quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 3,581 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Sage Therapeutics during the 4th quarter worth about $49,000. Ieq Capital LLC acquired a new position in Sage Therapeutics in the fourth quarter valued at approximately $57,000. US Bancorp DE increased its stake in Sage Therapeutics by 22.3% in the fourth quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 2,268 shares during the last quarter. Finally, Teacher Retirement System of Texas raised its holdings in Sage Therapeutics by 21.6% during the fourth quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company’s stock worth $75,000 after purchasing an additional 2,446 shares in the last quarter. 99.22% of the stock is owned by hedge funds and other institutional investors.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.